What is CJC + Ipamorelin Blend?
The CJC + Ipamorelin Blend combines CJC-1295 (no-DAC) and Ipamorelin in a single vial — the most studied GH-stimulating peptide stack in research. CJC-1295 (no-DAC) acts on GHRH receptors to amplify GH pulse amplitude, while Ipamorelin acts on ghrelin receptors to selectively trigger GH secretion. Together they engage two distinct GH-releasing pathways simultaneously, producing synergistic GH pulses that are significantly larger than either compound alone.
Research Benefits
- Dual-pathway GH stimulation: GHRH receptor (CJC) + ghrelin receptor (Ipamorelin) synergy
- Produces substantially larger GH pulses than either compound administered alone
- Supports body recomposition — simultaneous fat loss and lean muscle preservation
- Enhances deep slow-wave sleep quality through GH-mediated mechanisms
- Improves recovery from training — reduced DOMS and faster tissue repair
- Maintains the clean hormonal profile of Ipamorelin — no cortisol or prolactin elevation
Dosage & Protocol
The pre-blended 5+5mg vial (5mg CJC-1295 no-DAC + 5mg Ipamorelin) is reconstituted with bacteriostatic water. Typical research dose is 100–200 mcg of each compound per injection, 2–3 times daily. Administration before sleep and upon waking are the most studied windows. The blend simplifies dual-compound protocols into a single injection.
Frequently Asked Questions
This stack engages two independent GH-releasing pathways: GHRH receptors (CJC-1295) and ghrelin receptors (Ipamorelin). The combined effect produces 2–5x larger GH pulses than either compound alone, making it the most studied and widely used GH optimization stack in peptide research.
Yes. The pre-blended vial combines CJC-1295 no-DAC and Ipamorelin in a 1:1 ratio, eliminating the need to reconstitute two separate vials and calculate dual doses. One reconstitution, one injection — the same research protocol with significantly less preparation.
Research cycles typically run 8–16 weeks. IGF-1 levels generally peak within 4–6 weeks. Extended 16-week cycles show continued body composition improvements. Most protocols include a 4-week off period before resuming to prevent receptor desensitization.